{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:48:43Z","timestamp":1792154923895,"version":"4.4.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the Glasgow Prognostic Score (GPS) in predicting prognosis in patients with advanced hepatitis-B virus-related hepatocellular carcinoma (HBV-HCC) who are undergoing hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and toripalimab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>In this single-center retrospective study, patients with advanced HBV-HCC who received treatment with HAIC combined with lenvatinib and toripalimab from March 2019 to November 2021 were analyzed. The patients were divided into two groups based on GPS, and propensity score matching (PSM) was used to assess progression-free survival (PFS) and overall survival (OS) in both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 58 patients, 37 were included in the study. Thirteen patients were in the GPS score 0 group and 24 in the GPS score 1 group. After PSM, eight pairs were selected. Patients in the GPS score 0 group had significantly longer median PFS before (10.2 versus 4.3 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009) and after PSM (5.6 versus 1.9 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.026). Similarly, OS was significantly longer in the GPS score 0 group before (32.0 versus 9.7 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and after PSM (32.0 versus 8.6 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). GPS was an independent prognostic factor for OS, with borderline significance for PFS. In addition, tumor number was identified as an independent prognostic factor for PFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This exploratory study provides preliminary evidence that GPS may serve as a prognostic factor for patients with advanced HBV-related HCC who were receiving a triple-combination therapy, requiring further validation in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2567_25","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:00:11Z","timestamp":1790766011000},"page":"727-733","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of Glasgow prognostic score in patients with advanced hepatitis-B virus-related hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab"],"prefix":"10.4103","volume":"22","author":[{"given":"Ruizhi","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtong","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Vascular and Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanggang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Interventional Therapy, Shenzhen Second People\u2019s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"R1-20261016","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000530495","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)","volume":"12","author":"Zhou","year":"2023","journal-title":"Liver Cancer"},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, nccn clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20261016","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11427-017-9259-9","article-title":"42,573 cases of hepatectomy in china: A multicenter retrospective investigation","volume":"61","author":"Zhang","year":"2018","journal-title":"Sci China Life Sci"},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","article-title":"Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial","volume":"174","author":"Lai","year":"2022","journal-title":"Eur J Cancer"},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"15330338211063848","DOI":"10.1177\/15330338211063848","article-title":"Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma","volume":"20","author":"Xu","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"17588359211002720","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","article-title":"Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma","volume":"42","author":"Sun","year":"2024","journal-title":"Cancer Cell"},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.7150\/thno.71873","article-title":"Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"R10-20261016","first-page":"100070","article-title":"Comprehensive review of the vascular niche in regulating liver regeneration, fibrosis, and hepatocellular carcinoma","volume":"2","author":"Chen","year":"2025","journal-title":"Eng Med"},{"key":"R11-20261016","doi-asserted-by":"crossref","first-page":"e2133","DOI":"10.1097\/MD.0000000000002133","article-title":"Prognostic role of Glasgow prognostic score in patients with hepatocellular carcinoma: A systematic review and meta-analysis","volume":"94","author":"Li","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R12-20261016","first-page":"1921","volume":"34","author":"Kurosaki","year":"2020","journal-title":"Glasgow prognostic score (gps) and tumor response as biomarkers of nivolumab monotherapy in third- or later-line setting for advanced gastric cancer .In Vivo"},{"key":"R13-20261016","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3892\/mco.2017.1166","article-title":"Glasgow prognostic score predicts prognosis of intrahepatic cholangiocarcinoma","volume":"6","author":"Pan","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"R14-20261016","doi-asserted-by":"crossref","first-page":"637650","DOI":"10.3389\/fcell.2021.637650","article-title":"Prognostic value of c-reactive protein, Glasgow prognostic score, and c-reactive protein-to-albumin ratio in colorectal cancer","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R15-20261016","doi-asserted-by":"crossref","first-page":"875","DOI":"10.21873\/anticanres.16230","article-title":"Glasgow prognostic score predicts survival and recurrence pattern in patients with hepatocellular carcinoma after hepatectomy","volume":"43","author":"Kumamoto","year":"2023","journal-title":"Anticancer Res"},{"key":"R16-20261016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/MEG.0000000000002398","article-title":"Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: A multicenter analysis","volume":"34","author":"Tada","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.3748\/wjg.v21.i18.5582","article-title":"Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization","volume":"21","author":"Zhou","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R18-20261016","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1177\/0962280216658920","article-title":"Propensity score matching and complex surveys","volume":"27","author":"Austin","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"R20-20261016","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.3390\/cancers16142549","article-title":"Decoding the prognostic significance and therapeutic implications of inflammation-based scores in hepatocellular carcinoma: A comprehensive review","volume":"16","author":"Kotsifa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"110228","DOI":"10.1016\/j.intimp.2023.110228","article-title":"The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy","volume":"119","author":"Chen","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R22-20261016","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/02656736.2021.1876930","article-title":"Single-nodule hepatitis b virus-associated hepatocellular carcinoma smaller than 3 cm: Two phenotypes defined by cluster analysis and their association with the outcome of ablation as the first-line therapy","volume":"38","author":"Chen","year":"2021","journal-title":"Int J Hyperthermia"},{"key":"R23-20261016","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-induced immune imbalance in the development of hcc","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"R24-20261016","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"R25-20261016","doi-asserted-by":"crossref","first-page":"e7105","DOI":"10.1002\/cam4.7105","article-title":"Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma","volume":"13","author":"Fu","year":"2024","journal-title":"Cancer Med"},{"key":"R26-20261016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4103\/jcrt.jcrt_1515_25","article-title":"Thermal ablation versus hepatectomy in patients with liver metastases from RAS-mutated colorectal cancer","volume":"22","author":"Wen","year":"2026","journal-title":"J Cancer Res Ther"},{"key":"R27-20261016","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00428-016-2051-5","article-title":"CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia","volume":"470","author":"Semaan","year":"2017","journal-title":"Virchows Arch"},{"key":"R28-20261016","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4103\/jcrt.jcrt_614_25","article-title":"Prognostic value of alpha-fetoprotein and des-gamma-carboxyprothrombin in hepatocellular carcinoma treated with transarterial chemoembolization","volume":"21","author":"Liu","year":"2025","journal-title":"J Cancer Res Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2567_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:01:33Z","timestamp":1792152093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2567_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2567_25","relation":{},"ISSN":["1998-4138","0973-1482"],"issn-type":[{"value":"1998-4138","type":"print"},{"value":"0973-1482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-12-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}